Numis is delighted to have acted as joint financial adviser and broker to Clinigen Group plc on its £1.3bn buy-out by Triton Investment Management.
Clinigen is a global pharmaceutical services and products company focused on providing ethical access to medicines with a mission to deliver the right medicine to the right patient at the right time. The business operates from sites in North America, Europe, Africa and Asia Pacific.
Numis is proud of our long-standing relationship with Clinigen. It is a business we first IPO’d in 2012 and have supported the company on its organic and inorganic growth strategy in the years since.
The offer price of 925p per share, which was the seventh of seven unsolicited proposals from Triton, represented a 48% premium to the (ex-div) closing price and a 50% premium to the six-month volume weighted average (ex-div) price at close of business on 1 December 2021, the last business day before the start of the offer period.
The Numis team provided key input on value and tactics, as well as process management and shareholder insight.
“It is fantastic to see Numis once again providing a long-term client with quality, independent financial and tactical advice and robust shareholder insight. The successful execution of yet another substantial public to private transaction reinforces Numis’ excellent credentials as a leading financial adviser on UK public offers.”
This transaction is a great outcome for Clinigen and we are very proud of the team involved.
For further information, please reach out to your Numis representative.
The largest corporate broker in the UK by number of listed clients
Capital raising specialists in services including IPOs, equity issuance and block trades
Providing M&A expertise through a full suite of bespoke advice and solutions
Expert debt advice focused on robust and efficient corporate solutions
Drawing from our experience to deliver strong outcomes at IPO
Enabling the world’s most ambitious private companies to achieve their ambitions
We are the leading provider of in-depth, high quality research on UK listed companies
The largest, most experienced Sales Trading and Trading teams covering UK equities
Proactive advice combining in-depth research, distribution and execution